Daptomycin
LY146032, A21978C1 derivative, N-decanoyl-A21978C
Daptomycin is a cyclic lipopeptide antibiotic made by the soil bacterium Streptomyces roseosporus and licensed since 2003 for serious Gram-positive infections, including those caused by meticillin-resistant Staphylococcus aureus. Unlike most antibiotics it attacks the bacterial cell membrane rather than the cell wall, killing bacteria without bursting them. It works in skin and bloodstream infections but is inactivated by lung surfactant, so it does not treat pneumonia.
Mechanism
Daptomycin is inactive on its own. It first chelates calcium ions, which neutralises part of its negative charge and lets the decanoyl tail insert into the bacterial cytoplasmic membrane. Insertion is selective for membranes rich in phosphatidylglycerol, which is abundant in Gram-positive bacteria and scarce in mammalian cells. Once inserted, daptomycin oligomerises into larger assemblies that distort the membrane, cause potassium efflux and dissipate the membrane potential. Death follows without the cell lysing, which is why daptomycin releases comparatively little pro-inflammatory cell wall debris.
The older description of a simple ion-conducting pore has been refined. Work over the past decade indicates that daptomycin concentrates in fluid lipid domains and forms a tripartite complex with undecaprenyl-coupled cell envelope precursors, notably lipid II. This mislocalises the peripheral membrane proteins that organise cell division, including DivIVA, and derails peptidoglycan synthesis as a secondary consequence of membrane disorganisation. Resistance arises chiefly through gain-of-function mutations in mprF, which increases lysylation of phosphatidylglycerol and repels the calcium-daptomycin complex, and through mutations in the walKR (yycFG) two-component system that alter cell envelope homeostasis.
What the research shows
The skin infection programme pooled two randomised trials in 1092 enrolled patients (Arbeit 2004). Daptomycin 4 mg/kg once daily was compared with a penicillinase-resistant penicillin or vancomycin; clinical success among 902 clinically evaluable patients was 83.4% for daptomycin against 84.2% for comparators, meeting non-inferiority. Sixty-three per cent of daptomycin recipients required only four to seven days of therapy, against 33% of comparator patients.
The bacteraemia trial (Fowler 2006) randomised 246 patients with Staphylococcus aureus bacteraemia with or without endocarditis to daptomycin 6 mg/kg daily or to low-dose gentamicin plus an antistaphylococcal penicillin or vancomycin. Success rates were 44.2% with daptomycin and 41.7% with standard therapy, satisfying the non-inferiority margin. Microbiological failure with rising daptomycin minimum inhibitory concentrations occurred in a small number of patients, a signal that has persisted in practice.
The important negative result is pneumonia. A combined analysis of two phase 3 double-blind trials in community-acquired pneumonia (Pertel 2008; 834 patients in the intention-to-treat population) found daptomycin 4 mg/kg inferior to ceftriaxone, with cure rates of 70.9% against 77.4%. Notably, among patients who had received up to 24 hours of prior effective therapy the cure rates were similar (90.7% against 88.0%), which is why the paper is framed around the confounding effect of prior antibiotics. The authors concluded plainly that daptomycin is not effective for community-acquired pneumonia. The mechanistic explanation is that pulmonary surfactant binds and inactivates daptomycin, so alveolar concentrations of free drug are inadequate regardless of dose. This is one of the cleanest examples in antibacterial development of a drug failing for a site-specific pharmacological reason rather than a spectrum problem.
Later pragmatic and open-label randomised work, including a comparative effectiveness trial against vancomycin in complicated skin and skin-structure infection (Kauf 2015) and a phase 3b trial in elderly patients (Konychev 2013), has not overturned the picture of broad equivalence to vancomycin in skin infection with a different toxicity profile.
Evidence assessment
High-quality evidence
Audited and confirmed as strong. Two large randomised registration trials in complicated skin and skin-structure infection (Arbeit 2004, PMID 15227611), a randomised trial in Staphylococcus aureus bacteraemia and right-sided endocarditis (Fowler 2006, PMID 16914701), two supportive randomised trials, and current approved labelling from both the FDA and European regulators. All five citations survived verification with confirmed identifiers. The evidence base is genuinely strong for the licensed indications, and equally clear about where the drug fails: the pneumonia programme was negative (Pertel 2008, PMID 18444848) and the label states the drug is not indicated for pneumonia.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections Preclinical only
Clinical success 83.4% with daptomycin 4 mg/kg daily versus 84.2% with comparator (penicillinase-resistant penicillin or vancomycin) among clinically evaluable patients. Non-inferiority met. Sixty-three per cent of daptomycin recipients needed only four to seven days of therapy against 33% of comparator patients. Safety profiles were similar.
Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus Preclinical only
Success in 44.2% of daptomycin recipients (6 mg/kg daily) versus 41.7% of those given low-dose gentamicin plus an antistaphylococcal penicillin or vancomycin. Non-inferior for bacteraemia and right-sided endocarditis; renal adverse events were less frequent with daptomycin.
Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia Preclinical only
Negative result. Daptomycin 4 mg/kg daily produced lower cure rates than ceftriaxone (70.9% versus 77.4% in the intention-to-treat population). Among patients given up to 24 hours of prior effective therapy, cure rates were similar between arms (90.7% versus 88.0%), so the authors emphasised that even brief pre-treatment obscured the difference. Their stated conclusion was that daptomycin is not effective for community-acquired pneumonia; inactivation by pulmonary surfactant is the accepted mechanistic explanation.
An open-label, pragmatic, randomized controlled clinical trial to evaluate the comparative effectiveness of daptomycin versus vancomycin for the treatment of complicated skin and skin structure infection Preclinical only
No clinically meaningful difference in effectiveness between daptomycin and vancomycin for complicated skin and skin-structure infection under routine practice conditions, supporting the registration-trial finding of equivalence rather than superiority.
Safety and efficacy of daptomycin as first-line treatment for complicated skin and soft tissue infections in elderly patients: an open-label, multicentre, randomized phase IIIb trial Preclinical only
Daptomycin performed comparably to standard therapy as first-line treatment in an older population, with no new safety signal specific to age beyond the expected need for renal dose adjustment.
Safety
The characteristic toxicity is skeletal muscle injury. Creatine phosphokinase rises in a dose-related fashion and myopathy or, rarely, rhabdomyolysis can occur; labelling requires periodic creatine phosphokinase monitoring and consideration of stopping concurrent statins. Eosinophilic pneumonia is an uncommon but well-documented reaction, typically appearing after two to four weeks of therapy with fever, dyspnoea and pulmonary infiltrates; the FDA issued a specific safety communication about it in 2010. Peripheral neuropathy has been reported. Renal impairment prolongs exposure and requires dose interval adjustment. Clostridioides difficile infection can follow, as with any broad antibacterial. Emergence of reduced susceptibility during treatment of deep-seated infection is a recognised clinical problem, particularly with inadequate source control.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | Prescription-only medicine, originally authorised through the EU centralised procedure in January 2006 and now regulated by the MHRA. Licensed for complicated skin and soft tissue infections, and for right-sided infective endocarditis due to Staphylococcus aureus and associated bacteraemia. In practice it is a hospital-only intravenous agent, usually reserved for meticillin-resistant infection or where a glycopeptide is unsuitable. |
| United States | Approved by the FDA in September 2003 for complicated skin and skin-structure infections, with the indication extended in May 2006 to Staphylococcus aureus bloodstream infection including right-sided infective endocarditis. Prescription-only, intravenous. The label explicitly states daptomycin is not indicated for the treatment of pneumonia. |
| WADA (sport) | Not prohibited. Antibacterial agents including daptomycin do not appear on the WADA Prohibited List, in or out of competition. |
Questions
Pulmonary surfactant, the lipid-protein film lining the alveoli, binds daptomycin and inactivates it. Free drug concentrations in the alveolar space therefore stay below what is needed to kill bacteria, no matter how high the plasma level. A combined analysis of two phase 3 double-blind trials in community-acquired pneumonia found lower cure rates with daptomycin than with ceftriaxone and concluded the drug is not effective for that infection, and the approved labelling states it is not indicated for pneumonia. It can still be appropriate for bloodstream infection that has seeded the lung from elsewhere, such as septic pulmonary emboli from right-sided endocarditis.
They attack different targets. Vancomycin is a glycopeptide that blocks cell wall building by binding the D-Ala-D-Ala terminus of peptidoglycan precursors. Daptomycin is a lipopeptide that inserts into the cell membrane itself and collapses the membrane potential. That difference matters clinically: daptomycin usually retains activity against vancomycin-resistant enterococci and against strains with reduced vancomycin susceptibility, and it is bactericidal in a concentration-dependent way. Their toxicity profiles differ too, with vancomycin more associated with kidney injury and daptomycin with muscle enzyme elevation.
Bacteria can, and this is a real clinical problem rather than a theoretical one. The commonest route is gain-of-function mutation in mprF, which adds lysine groups to membrane phosphatidylglycerol, increasing the net positive surface charge and repelling the calcium-daptomycin complex. Mutations in the walKR two-component regulatory system also reduce susceptibility. Emergence during treatment is most often seen in deep-seated infections such as endocarditis or osteomyelitis where the bacterial burden is high and surgical source control is incomplete.